Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0044-1785220
Original Article

Molecular Profiling of High-Grade B-Cell Non-Hodgkin Lymphomas and Its Clinicopathologic Correlation in an Indian Tertiary Cancer Care Center

Nikhil Sebastian 
1   Department of Medical Oncology, Apollo Cancer Centre, Chennai, Tamil Nadu, India
,
Shoaib Nawaz P. N
1   Department of Medical Oncology, Apollo Cancer Centre, Chennai, Tamil Nadu, India
,
Ramya Ananthkrishnan
1   Department of Medical Oncology, Apollo Cancer Centre, Chennai, Tamil Nadu, India
,
J. Kumanan
1   Department of Medical Oncology, Apollo Cancer Centre, Chennai, Tamil Nadu, India
,
Chitra Chandran
2   Department of Molecular Pathology, Apollo Hospitals, Chennai, Tamil Nadu, India
,
Thirumalairaj Raja
1   Department of Medical Oncology, Apollo Cancer Centre, Chennai, Tamil Nadu, India
› Author Affiliations Source of Funding None.
› Further Information
   Permissions and Reprints

Abstract

Introduction Double-expressor and double-hit lymphomas (DHL) are known to be more aggressive and have poor outcomes with standard chemotherapy regimens.

Objectives To assess the incidence of DHL and triple-hit lymphomas (THL) and correlate them with clinicopathologic parameters.

Materials and Methods Patients who were diagnosed with high-grade lymphomas from April 2021 to September 2022 were prospectively followed up, and details comprising clinical and pathological parameters, including the immunohistochemistry expression status and gene rearrangements of MYC, BCL2, and BCL6, were recorded.

Results The incidence of DHL and THL in our study was 16.43%. The separate incidence of the DHL-BCL2, DHL-BCL6, and THL groups was 16.43, 13.69, and 2.73%, respectively. The germinal center B cell subtype of histology was predominantly seen in DHLs. MYC, BCL2, and BCL6 expressions do not correlate well with translocations of these genes.

Conclusion Double protein expression cannot be used for screening to decide which patients should undergo fluorescence in situ hybridization, as this would result in missing 4.5% of DHLs.

Keywords

double-hit lymphoma - triple-hit lymphoma - double-expressor lymphoma - triple-expressor lymphoma - double protein expression

Patient Consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given their consent for her images and other clinical information to be reported in the journal. The patient understands that their names and initials will not be published, and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.


Ethical Considerations

The study was submitted and cleared by the Institutional Ethical Committee-Biomedical Research, Apollo Hospitals, Chennai, EC Reg No. EC/NEW/INST/2020/527 NABH Certification No. EC-CT-2018-0045 on April 29, 2021, as per approval number ASH-DNB-042/04-21. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All patients included in the study were provided with a patient information leaflet and consented to be part of the study on the informed consent form.




Publication History

Article published online:
10 April 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    CrossrefPubMedGoogle Scholar
  • 2 Nair R, Arora N, Mallath MK. Epidemiology of non-Hodgkin's lymphoma in India. Oncology 2016; 91 (Suppl. 01) 18-25
    CrossrefPubMedGoogle Scholar
  • 3 Swerdlow SH, Campo E, Harris NL. et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Vol. 1.. Lyon Cedex, France: International Agency for Research on Cancer (IARC); 2017
    Google Scholar
  • 4 Hu S, Xu-Monette ZY, Tzankov A. et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 121 (20) 4021-4031 , quiz 4250
    CrossrefPubMedGoogle Scholar
  • 5 Johnson NA, Slack GW, Savage KJ. et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30 (28) 3452-3459
    CrossrefPubMedGoogle Scholar
  • 6 Scott DW, Wright GW, Williams PM. et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123 (08) 1214-1217
    CrossrefPubMedGoogle Scholar
  • 7 Landsburg DJ, Petrich AM, Abramson JS. et al. Impact of oncogene rearrangement patterns on outcomes in double-hit non-Hodgkin lymphoma. Cancer 2016; 122 (04) 559-564
    CrossrefPubMedGoogle Scholar
  • 8 Sermer D, Bobillo S, Seshan V, Dogan A, Younes A. Clinical significance and outcomes in patients with diffuse large B-cell lymphoma (dlbcl) harboring extra copies [ec] and/or translocations [tl] of Myc, Bcl2, and Bcl6. Hematol Oncol 2019; 37 (S2): 349-350
    CrossrefGoogle Scholar
  • 9 Ting CY, Chang KM, Kuan JW. et al. Clinical significance of BCL2, C-MYC, and BCL6 genetic abnormalities, Epstein-Barr virus infection, CD5 protein expression, germinal center B cell/non-germinal center B-cell subtypes, co-expression of MYC/BCL2 proteins and co-expression of MYC/BCL2/BCL6 proteins in diffuse large B-cell lymphoma: a clinical and pathological correlation study of 120 patients. Int J Med Sci 2019; 16 (04) 556-566
    CrossrefPubMedGoogle Scholar
  • 10 Huang S, Nong L, Wang W. et al. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma. Diagn Pathol 2019; 14 (01) 81
    CrossrefPubMedGoogle Scholar
  • 11 Zhang Y, Wang H, Ren C. et al. Correlation between C-MYC, BCL-2, and BCL-6 protein expression and gene translocation as biomarkers in diagnosis and prognosis of diffuse large B-cell lymphoma. Front Pharmacol 2019; 9: 1497
    CrossrefPubMedGoogle Scholar
  • 12 Salam DSDA, Thit EE, Teoh SH, Tan SY, Peh SC, Cheah SC. C-MYC, BCL2 and BCL6 translocation in B-cell non-Hodgkin lymphoma cases. J Cancer 2020; 11 (01) 190-198
    CrossrefPubMedGoogle Scholar
  • 13 Hans CP, Weisenburger DD, Greiner TC. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103 (01) 275-282
    CrossrefPubMedGoogle Scholar
  • 14 Jais JP, Molina TJ, Ruminy P. et al. Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. Haematologica 2017; 102 (10) e404-e406
    CrossrefPubMedGoogle Scholar
  • 15 Mehta A, Verma A, Gupta G, Tripathi R, Sharma A. Double hit and double expresser diffuse large B cell lymphoma subtypes: discrete subtypes and major predictors of overall survival. Indian J Hematol Blood Transfus 2020; 36 (04) 627-634
    CrossrefPubMedGoogle Scholar
  • 16 Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJD, Schuster SJ. ‘Double-Hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Haematol 2014; 166 (03) 369-374
    CrossrefPubMedGoogle Scholar
  • 17 Barraclough A, Alzahrani M, Schmidt Ettrup M. et al. Impact of immunohistochemistry-defined cell of origin and MYC rearrangements on outcomes in patients with PET-defined stage I/II diffuse large B-cell lymphoma treated with R-CHOP ± radiotherapy: an International Multi-Center Retrospective Study. Blood 2017; 130 (Suppl. 01) 415
    Google Scholar
  • 18 Kluk MJ, Ho C, Yu H. et al. MYC immunohistochemistry to identify MYC-driven B-cell lymphomas in clinical practice. Am J Clin Pathol 2016; 145 (02) 166-179
    CrossrefPubMedGoogle Scholar
  • 19 Sakr H, Cook JR. Identification of “double hit” lymphomas using updated WHO criteria: insights from routine MYC immunohistochemistry in 272 consecutive cases of aggressive B-cell lymphomas. Appl Immunohistochem Mol Morphol 2019; 27 (06) 410-415
    CrossrefPubMedGoogle Scholar
  • 20 Horn H, Ziepert M, Becher C. et al; German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121 (12) 2253-2263
    CrossrefPubMedGoogle Scholar